New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

February 11, 2008 — Investigators have found that insulin-like growth factor binding protein 7 (IGFBP7), a secreted protein, dramatically influences the ability of an activating BRAF mutation to ...

BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...

This recent readout follows successful data from another combination including Braftovi in mCRC.

Biomedical engineers have demonstrated that one of the most dangerous mutations found in skin cancers might moonlight as a pathway to mending a broken heart. The genetic mutation in the protein BRAF, ...